• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    5/17/24 12:31:07 PM ET
    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ABIO alert in real time by email

    Gainers

    • Akanda (NASDAQ:AKAN) shares increased by 103.8% to $0.27 during Friday's regular session. The company's market cap stands at $8.6 million.
    • NovaBay Pharmaceuticals (AMEX:NBY) shares rose 48.66% to $0.18. The company's market cap stands at $6.7 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 29.77% to $8.63. The company's market cap stands at $8.9 million. As per the news, the Q1 earnings report came out 3 days ago.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 27.23% to $1.13. The market value of their outstanding shares is at $6.8 million.
    • Onconetix (NASDAQ:ONCO) stock increased by 26.73% to $0.18. The market value of their outstanding shares is at $3.9 million.
    • Doximity (NYSE:DOCS) stock increased by 17.98% to $28.01. The market value of their outstanding shares is at $5.2 billion. The company's, Q4 earnings came out yesterday.

    Losers

    • Lucy Scientific Discovery (NASDAQ:LSDI) shares decreased by 21.1% to $1.25 during Friday's regular session. The company's market cap stands at $2.2 million.
    • SINTX Techs (NASDAQ:SINT) shares decreased by 15.36% to $0.12. The market value of their outstanding shares is at $14.5 million. The company's, Q1 earnings came out 4 days ago.
    • Bone Biologics (NASDAQ:BBLG) shares declined by 15.01% to $1.87. The company's market cap stands at $1.6 million. The company's, Q1 earnings came out 3 days ago.
    • ARCA biopharma (NASDAQ:ABIO) stock decreased by 14.75% to $3.41. The company's market cap stands at $49.4 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares fell 14.19% to $0.72. The company's market cap stands at $15.5 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) shares declined by 13.09% to $0.22. The company's market cap stands at $3.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO
    $AKAN
    $BBLG
    $CDIO

    CompanyDatePrice TargetRatingAnalyst
    Doximity Inc.
    $DOCS
    2/9/2026$34.00Hold → Buy
    Canaccord Genuity
    Doximity Inc.
    $DOCS
    2/6/2026$40.00Underweight → Neutral
    Analyst
    Doximity Inc.
    $DOCS
    1/20/2026$55.00Equal Weight → Overweight
    Wells Fargo
    Doximity Inc.
    $DOCS
    1/9/2026$59.00Outperform
    RBC Capital Mkts
    Doximity Inc.
    $DOCS
    1/8/2026Hold → Buy
    Truist
    Doximity Inc.
    $DOCS
    12/15/2025$65.00Equal-Weight → Overweight
    Morgan Stanley
    Doximity Inc.
    $DOCS
    12/9/2025$63.00Overweight
    Barclays
    Doximity Inc.
    $DOCS
    11/21/2025$65.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Wampler Kira Scherer converted options into 2,000 shares and sold $52,000 worth of shares (2,000 units at $26.00) (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    3/5/26 4:23:03 PM ET
    $DOCS
    EDP Services
    Technology

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico

    Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most active industrial corridors and fastest-growing state economies.The network was constructed following the execution of a 20-year long-term dark fiber lease agreement with Telefónica, the Spanish multinationa

    2/27/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

    BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Dire

    2/23/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Doximity upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Doximity from Hold to Buy and set a new price target of $34.00

    2/9/26 6:58:22 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Analyst with a new price target

    Analyst upgraded Doximity from Underweight to Neutral and set a new price target of $40.00

    2/6/26 8:05:27 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Doximity from Equal Weight to Overweight and set a new price target of $55.00

    1/20/26 8:43:16 AM ET
    $DOCS
    EDP Services
    Technology

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    SEC Filings

    View All

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:05:39 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

    DEFA14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/2/26 5:21:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Doximity to Release Fiscal 2026 Third Quarter Results on February 5, 2026

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2025 after market close on February 5, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inclu

    1/15/26 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $AKAN
    $BBLG
    $CDIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    SC 13G/A - Doximity, Inc. (0001516513) (Subject)

    11/14/24 5:22:01 PM ET
    $DOCS
    EDP Services
    Technology